Daclizumab versus rabbit antithymocyte globulin in high-risk renal transplants: Five-year follow-up of a randomized study

American Journal of Transplantation

Volumn 15, Issue 7, 2015, Pages 1923-1932

  Hellemans, R ^a   Hazzan, M ^b   Durand, D ^c   Mourad, G ^d   Lang, P ^e   Kessler, M ^f   Charpentier, B ^g   Touchard, G ^h   Berthoux, F ⁱ   Merville, P ^j   Ouali, N ^k   Squifflet, J P ^l   Bayle, F ^m   Wissing, K M ⁿ   Noel C ^b   Abramowicz, D ^a  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b Hôpital   (France)

^c CHU RANGUEIL   (France)

^d LAPEYRONIE HOSPITAL   (France)

^e HENRI MONDOR HOSPITAL   (France)

^f UNIVERSITÉ DE LORRAINE   (France)

^g Service de Néphrologie   (France)

^h University of Poitiers   (France)

ⁱ HÔPITAL NORD   (France)

^j HÔPITAL PELLEGRIN   (France)

^k HÔPITAL TENON   (France)

^l CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^m GRENOBLE UNIVERSITY HOSPITAL   (France)

ⁿ UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

more..

Author keywords

clinical research practice; fusion proteins and monoclonal antibodies: basiliximab daclizumab; graft survival; immunosuppressant; Immunosuppressant; kidney transplantation nephrology; polyclonal preparations: rabbit antithymocyte globulin

Indexed keywords

ANTIHYPERTENSIVE AGENT; AZATHIOPRINE; CYCLOSPORIN; DACLIZUMAB; METHYLPREDNISOLONE; MYCOPHENOLATE MOFETIL; PANEL REACTIVE ANTIBODY; PREDNISONE; RAPAMYCIN; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; LYMPHOCYTE ANTIBODY; MONOCLONAL ANTIBODY;

ACUTE GRAFT REJECTION; ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BIOPSY PROVEN ACUTE REJECTION; CADAVER; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; END STAGE RENAL DISEASE; FEMALE; FOLLOW UP; GRAFT RECIPIENT; GRAFT REJECTION; GRAFT SURVIVAL; HIGH RISK PATIENT; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY DONOR; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; STEROID RESISTANT REJECTION; SURVIVAL RATE; TREATMENT DURATION; ANIMAL; COMPARATIVE STUDY; DRUG EFFECTS; GLOMERULUS FILTRATION RATE; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TEST; POSTOPERATIVE COMPLICATION; PROGNOSIS; PROSPECTIVE STUDY; RABBIT; RISK FACTOR;

ADULT; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTILYMPHOCYTE SERUM; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; PROSPECTIVE STUDIES; RABBITS; RISK FACTORS;

EID: 84931572892     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.13191     Document Type: Article

References (21)

1. Wu O, Levy AR, Briggs A, Lewis G, Jardine A,. Acute rejection and chronic nephropathy: A systematic review of the literature. Transplantation 2009; 87: 1330-1339.
2. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009; 9: S1-155.
3. Webster AC, Ruster LP, McGee R, et al., Interleukin 2 receptor antagonists for kidney transplant recipients. Cochrane Database Syst Rev 2010; 1: CD003897.
4. Noël C, Abramowicz D, Durand D, et al., Daclizumab versus antithymocyte globulin in high-immunological-risk renal transplant recipients. J Am Soc Nephrol 2009; 20: 1385-1392.
5. Brennan DC, Daller JA, Lake KD, Cibrik D, Del Castillo D,. Thymoglobulin Induction Study Group. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med 2006; 355: 1967-1977.
6. Soulillou JP, Cantarovich D, Le Mauff B, et al., Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts. N Engl J Med 1990; 322: 1175-1182.
7. Kriaa F, Hiesse C, Alard P, et al., Prophylactic use of the anti-IL-2 receptor monoclonal antibody LO-Tact-1 in cadaveric renal transplantation: Results of a randomized study. Transplant Proc 1993; 25: 817-819.
8. Lebranchu Y, Bridoux F, Büchler M, et al., Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy. Am J Transplant 2002; 2: 48-56.
9. Kyllönen LE, Eklund BH, Pesonen EJ, Salmela KT,. Single bolus antithymocyte globulin versus basiliximab induction in kidney transplantation with cyclosporine triple immunosuppression: Efficacy and safety. Transplantation 2007; 84: 75-82.
10. Racusen LC, Solez K, Colvin RB, et al., The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713-723.
11. ERA-EDTA Registry. ERA-EDTA Registry Annual Report 2011. Academic Medical Center, Department of Medical Informatics, Amsterdam, The Netherlands, 2013. Available at: http://www.era-edta-reg.org/files/annualreports/pdf/AnnRep2011.pdf Accessed June 23, 2014.
12. Gondos A, Döhler B, Brenner H, Opelz G,. Kidney graft survival in Europe and the United States: Strikingly different long-term outcomes. Transplantation 2013; 95: 267-274.
13. Knoll GA,. Proteinuria in kidney transplant recipients: Prevalence, prognosis, and evidence-based management. Am J Kidney Dis 2009; 54: 1131-1144.
14. Kim MJ, Tsinalis D, Franz S, et al., ATG-Fresenius or daclizumab induction therapy in immunologically high risk kidney recipients: A prospective randomized pilot trial. Ann Transplant 2008; 13: 21-27.
15. Popat R, Syed A, Puliatti C, Cacciola R,. Outcome and cost analysis of induction immunosuppression with IL2Mab or ATG in DCD kidney transplants. Transplantation 2014; 97: 1161-1165.
16. Brennan DC, Schnitzler MA,. Long-term results of rabbit antithymocyte globulin and basiliximab induction. N Engl J Med 2008; 359: 1736-1738.
17. Opelz G, Naujokat C, Daniel V, Terness P, Döhler B,. Disassociation between risk of graft loss and risk of non-Hodgkin lymphoma with induction agents in renal transplant recipients. Transplantation 2006; 81: 1227-1233.
18. Morgan RD, O'Callaghan JM, Knight SR, Morris PJ,. Alemtuzumab induction therapy in kidney transplantation: A systematic review and meta-analysis. Transplantation 2012; 93: 1179-1188.
19. Hanaway MJ, Woodle ES, Mulgaonkar S, et al., INTAC Study Group. Alemtuzumab induction in renal transplantation. N Engl J Med 2011; 364: 1909-1919.
20. Iyer HS, Jackson AM, Zachary AA, Montgomery RA,. Transplanting the highly sensitized patient: Trials and tribulations. Curr Opin Nephrol Hypertens 2013; 22: 681-688.
21. Montgomery RA, Lonze BE, King KE, et al., Desensitization in HLA-incompatible kidney recipients and survival. N Engl J Med 2011; 365: 318-326.